NASDAQ:FATE

Fate Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FATE

*Your capital is at risk

$2.22

-0.350 (-13.62%)

At Close: Jun 03, 2026

Fate Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 69.21. In total, the insiders bought 34.41M and sold 16.73M FATE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	69.21
● Buy	34.41M shares
● Sell	16.73M shares
71% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Apr 20, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 69.21. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 20, 2026 Sell	Common Stock S-Sale	Valamehr Bahram President And CEO	CEO / President	28 946 Value: $54.5K
May 20, 2026 Sell	Common Stock S-Sale	Tahl Cindy See Remarks	Officer	25 590 Value: $48.1K
May 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Tahl Cindy See Remarks	Officer	122 220 Value: $161.3K
May 06, 2026 Buy	Common Stock M-Exempt	Tahl Cindy See Remarks	Officer	122 220 Value: $161.3K
May 06, 2026 Buy	Common Stock M-Exempt	Tahl Cindy See Remarks	Officer	44 444 Value: $46.7K
May 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Tahl Cindy See Remarks	Officer	44 444 Value: $46.7K
May 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Rastetter William H Director	Director	25 000 Value: $42.3K
May 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Epstein Robert S Director	Director	25 000 Value: $42.3K
May 05, 2026 Buy	Common Stock M-Exempt	Epstein Robert S Director	Director	25 000 Value: $42.3K
May 05, 2026 Buy	Common Stock M-Exempt	Rastetter William H Director	Director	25 000 Value: $42.3K
Apr 20, 2026 Sell	Cash-settled Swaps J-Other	Redmile Group, Llc	Director	266 280 Value: $1.56M
Apr 20, 2026 Buy	Cash-settled Swaps J-Other	Redmile Group, Llc	Director	266 280 Value: $1.56M
Apr 20, 2026 Sell	Class A Convertible Preferred Stock J-Other	Redmile Group, Llc	Director	162 013 Value: $0
Apr 20, 2026 Sell	Common Stock J-Other	Redmile Group, Llc	Director	8 977 624 Value: $0
Apr 20, 2026 Sell	Cash-settled Swaps J-Other	Redmile Group, Llc	Director	266 280 Value: $804.2K
Apr 20, 2026 Buy	Class A Convertible Preferred Stock J-Other	Redmile Group, Llc	Director	162 013 Value: $225.2K
Apr 20, 2026 Buy	Common Stock J-Other	Redmile Group, Llc	Director	8 977 624 Value: $12.5M
Apr 20, 2026 Buy	Pre-Funded Warrants to Purchase Common Stock J-Other	Redmile Group, Llc	Director	3 691 324 Value: $4K
Apr 20, 2026 Buy	Cash-settled Swaps J-Other	Redmile Group, Llc	Director	266 280 Value: $804.2K
Apr 20, 2026 Sell	Pre-Funded Warrants to Purchase Common Stock J-Other	Redmile Group, Llc	Director	3 691 324 Value: $4K
Jan 15, 2026 Buy	Common Stock A-Award	Valamehr Bahram President And CEO	CEO / President	335 000 Value: $351.8K
Jan 15, 2026 Buy	Stock Option (Right to Buy) A-Award	Valamehr Bahram President And CEO	CEO / President	1 300 000 Value: $1.37M
Jan 15, 2026 Buy	Stock Option (Right to Buy) A-Award	Tahl Cindy See Remarks	Officer	400 000 Value: $420.0K
Jan 15, 2026 Buy	Common Stock A-Award	Tahl Cindy See Remarks	Officer	100 000 Value: $105.0K
Jan 15, 2026 Buy	Common Stock A-Award	Adawi Kamal Chief Financial Officer	C-Suite Officer	25 000 Value: $26.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT FATE THERAPEUTICS

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...

Read Full Profile Here